Kirtland Poss, President & CEO, Director
Mr. Poss is co-founder, President and CEO of BioAnalytix. Previously, Mr. Poss founded and ran the molecular imaging company VisEn Medical as President and CEO from its early technology platform formation in 2000 through product development, worldwide commercialization, pharmaceutical partnerships, and M&A with PerkinElmer in 2010. In his role with VisEn, Mr. Poss led the development, launch and commercialization of multiple molecular imaging system and agent product lines, and also ran several of VisEn’s strategic partnerships with leading pharmaceutical companies and clinical research centers in applying VisEn’s molecular imaging agents in pharmaceutical development pipelines and clinical trials. Before VisEn, Mr. Poss worked in healthcare business strategy consulting for Kendall Strategies in Cambridge, MA, and prior to that he worked in scientific research at the Center for Molecular Imaging Research at the Massachusetts General Hospital and Harvard Medical School. He is a co-author on several scientific publications and multiple patents in the fields of biomarker imaging and pharmaceutical development.
Alfonso Chang, CFA, Director
Alfonso Chang, CFA is a Managing Director of Relativity Healthcare Partners (“RHCP”), an investment group dedicated to providing growth capital to emerging healthcare companies. Examples of investments by RHCP affiliated funds include Curative Medical and CHC Healthcare Group (TPE: 4164). Concurrently, Mr. Chang is a Managing Director of The AC3 Group, a boutique strategy consultancy. As a strategist, he advises mainly healthcare companies on financial and strategic topics, including alliances, corporate finance, deal structuring, lifecycle management, marketing, product development /management, and strategic planning. For over fifteen years, he has provided counsel to leading global companies, and he has worked with products at various stages of development (clinical to commercial) and sizes (niche to blockbuster). For RHCP, he uses his expertise to identify and structure investment opportunities and to provide strategic guidance to portfolio companies. Mr. Chang is a holder of the right to use the Chartered Financial Analyst designation, has an MBA from the University of Michigan, and has a BSE in chemical engineering from the University of Pennsylvania. He is a member of the New York Society of Security Analysts.
Michael Chao, MD, Director
Michael Chao, MD is a Managing Director of MAL Investment Company, an investment group dedicated to providing capital to companies developing promising technologies and/or offering novel services to address unmet needs. As a financier, Dr. Chao concentrates on investments that build preeminent healthcare companies. He has been involved in investments with Ovagene Oncology and Ansun Biopharma. He serves on the board of Tanvex Biologics and served on the board of Owl Biomedical through its successful sale to Miltenyi Biotec. Furthermore, Dr. Chao maintains a direct link to the health community as a staff physician at the US Department of Veterans Affairs healthcare system, providing medical and surgical care for veterans and combat veterans from current and prior military conflicts. With this position, Dr. Chao is able to stay current with medical practices and advancements. Dr. Chao received his MD from University of California, Irvine and his BA in Biology from the University of Pennsylvania. He has authored several articles with other physicians, and has presented medical findings at various societal meetings.
Robert Garnick, PhD, Director
Dr. Garnick has over 30 years of experience in drug and biologic pharmaceutical development. He was formerly the Senior Vice President of Regulatory, Quality and Compliance at Genentech, Inc. Dr. Garnick spent 24 years at Genentech as a pioneer in the biotechnology industry, and while at Genentech was responsible for the approval of over 17 drugs, biologics and medical devices. He has extensive experience in analytical methodology, process validation, the regulatory review process both in the US and Europe and in risk assessments in clinical development. He has authored numerous scientific papers and has given numerous keynote presentations to the pharmaceutical Industry.
Barry Karger, PhD, Co-founder, Chief Scientific Advisor and Board Observer
Barry Karger is co-founder of BioAnalytix and is the James L. Waters Chair in Analytical Chemistry and the Founding Director of the Barnett Institute of Chemical and Biological Analysis at Northeastern University in Boston, MA. Dr. Karger has been an active researcher with 350 publications and 45 patents in the field of bioanalytical chemistry, with particular emphasis in liquid chromatography, capillary electrophoresis and mass spectrometry. He has received many honors including three American Chemical Society awards, the prestigious Bergman Medal from the Swedish Chemical Society, and the Herovsky Gold Medal from the Czech Academy of Sciences, and recently the Beckman Medal. Dr. Karger has been a major contributor to the development of HPLC, and his technology in capillary electrophoresis played a significant role in the Human Genome Project. His recent interests are in the development of new technologies for proteomics, especially trace level LC/MS analysis of proteins in biological matrices, and comprehensive characterization of complex protein structures. He is also actively involved in the development of new technologies and advanced methods to characterize biopharmaceuticals in the biotechnology industry.